New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE:BSX) concerning potential violations of the federal securities laws.On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, appro ...

New York, New York--(Newsfile Corp. - February 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws.On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, appr ...

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for the fourth quarter, but management indicated confidence in only about 15% growth going forward, which is significantly lower than the market's expectation of approximately 25% [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential alternative to traditional thermal ablation procedures [3]. - Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has made substantial investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - The company emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4]. Stock Market Reaction - Following the earnings release, Boston Scientific's shares fell by 17.5%, reaching a 52-week low of $75.50, indicating a negative market reaction to the earnings report and growth outlook [5].

Core Insights - Boston Scientific Corporation reported fourth-quarter 2025 results, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales fell short of consensus estimates by approximately $43 million [2][4] - The electrophysiology market is rapidly growing, with Boston Scientific's pulsed field ablation technology positioned as a potential alternative to traditional thermal ablation procedures [3] - Following the earnings release, Boston Scientific's shares dropped 17.5%, reaching a 52-week low of $75.50, indicating market reaction to the company's guidance on growth expectations [6] Company Performance - Boston Scientific's electrophysiology segment reported sales of $890 million, below the $933 million consensus estimate, despite being a key growth driver for the company [2] - The company had previously projected organic growth of 11% to 13% for Q4 2025, but management indicated confidence in only approximately 15% growth going forward, contrasting with market expectations of around 25% [4][5] Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with expectations that global penetration of pulsed field ablation technology will reach 50% by the end of 2025 and approximately 80% by 2028 [3] - Boston Scientific's acquisition of Farapulse in 2021 has led to significant investments in manufacturing capacity and physician training programs to support growth in this segment [3]